PLYMOUTH
MEETING, Pa., Nov. 15,
2023 /PRNewswire/ -- Harmony Biosciences Holdings,
Inc. ("Harmony" or the "Company") (Nasdaq: HRMY), a pharmaceutical
company dedicated to developing and commercializing innovative
therapies for patients with rare neurological diseases, ranks
25th on the Deloitte Technology Fast 500™ for growing
revenues 7,204% from fiscal year 2019 to 2022.
Harmony Biosciences ranked 8th among the 87 life
science companies recognized this year, placing it among the
fastest-growing companies across the life science, technology,
media, fintech, and energy sectors in North America.
"Harmony is a growth story and our remarkable success is a
testament to the strength of our business and our commitment to
delivering novel treatments for people living with rare
neurological disorders," said Jeffrey M.
Dayno, MD, President and Chief Executive Officer of Harmony
Biosciences. "It's an honor to be recognized as one of the
fastest-growing companies in North
America across industry sectors and we look forward to
building upon this growth in the future."
About the 2023 Deloitte Technology Fast 500
Now in its
29th year, the Deloitte Technology Fast 500 provides a
ranking of the fastest-growing technology, media,
telecommunications, life sciences, fintech, and energy tech
companies — both public and private — in North America. Technology Fast 500 award
winners are selected based on percentage fiscal year revenue growth
from 2019 to 2022.
In order to be eligible for Technology Fast 500 recognition,
companies must own proprietary intellectual property or technology
that is sold to customers in products that contribute to a majority
of the company's operating revenues. Companies must have base-year
operating revenues of at least US$50,000, and current-year operating revenues of
at least US$5 million. Additionally,
companies must be in business for a minimum of four years and be
headquartered within North
America.
About Harmony Biosciences
At Harmony Biosciences, we specialize in developing and delivering
treatments for rare neurological diseases that others often
overlook. We believe that where empathy and innovation meet, a
better life can begin for people living with neurological diseases.
Established by Paragon Biosciences, LLC, in 2017 and headquartered
in Plymouth Meeting, PA, our team
of experts from a wide variety of disciplines and experiences is
driven by our shared conviction that innovative science translates
into therapeutic possibilities for our patients, who are at the
heart of everything we do. For more information, please visit
www.harmonybiosciences.com.
About Deloitte
Deloitte provides industry-leading audit, consulting, tax and
advisory services to many of the world's most admired brands,
including nearly 90% of the Fortune 500® and more than
8,500 U.S.-based private companies. At Deloitte, we strive to live
our purpose of making an impact that matters by creating trust
and confidence in a more equitable society. We leverage our unique
blend of business acumen, command of technology, and strategic
technology alliances to advise our clients across industries as
they build their future. Deloitte is proud to be part of the
largest global professional services network serving our clients in
the markets that are most important to them. Bringing more than 175
years of service, our network of member firms spans more than 150
countries and territories. Learn how Deloitte's approximately
457,000 people worldwide connect for impact at
www.deloitte.com.
Harmony Biosciences Media Contact:
Cate McCanless
202-641-6086
cmccanless@harmonybiosciences.com
Harmony Biosciences Investor Contact:
Luis Sanay, CFA
445-235-8386
lsanay@harmonybiosciences.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/harmony-biosciences-ranked-among-top-25-fastest-growing-companies-in-north-america-on-the-2023-deloitte-technology-fast-500-301988289.html
SOURCE Harmony Biosciences